The Need for Glycemic Trials in Type 2 Diabetes
- Carlos Abraira, MD and
- William Duckworth, MD
Abstract
In Brief
Glycemic control is a well-established treatment objective in diabetes care. However, the effectiveness and specific goals of glycemic control are not yet known for older type 2 diabetic patients with advanced complications and suboptimal response to current treatments. Therefore, current glycemic guidelines for such patients are variable. This article presents the rationale for ongoing long-term clinical trials to answer these questions and reviews the demonstrated effectiveness of hypertension and dyslipidemia control in reducing both microvascular and macrovascular complications.
Footnotes
-
Carlos Abraira, MD, is a professor of medicine at the University of Miami VA Medical Center in Miami, Fla. William Duckworth, MD, is director of diabetes research at the VA Medical Center, a research professor at Arizona State University, and a professor of clinical medicine at the University of Arizona, Phoenix, campus in Phoenix, Ariz. The authors are co-chairmen of the VA Diabetes Trial.
-
Note of disclosure: Dr. Abraira has received honoraria for speaking engagements from Aventis and research support from Novo Nordisk Pharmaceuticals, Inc., GlaxoSmithKline, Inc., and Aventis, all of which make pharmaceutical products for the control of glycemia in diabetes.
- American Diabetes Association
